Chinese, Canadian Researchers ID Anti-Bird Flu Compound
This article was originally published in PharmAsia News
Hong Kong and Canadian scientists working on a genome technology report found a compound that inhibits the H5N1 bird flu virus. The team said it tested 20 compounds and found one it labeled "compound-1" that inhibits neuraminidase involved in viral replication. The compound was found to operate at a level similar to oseltamivir, the active ingredient in Roche's Tamiflu, known to be losing its effectiveness against the virus. The identified compound was able to bind to the neuraminidase of the virus and, according to the researchers, might overcome the drug resistance. (Click here for more
You may also be interested in...
This month’s column covers deals announced between 1-23 April 2020.
Celltrion’s Truxima has become the first rituximab biosimilar, and just the second biosimilar overall, to be prequalified by the WHO.
EU MDR Panel Discussion: Why An Extra Year Is Not Really A Delay For The MDR – How To Survive Changing And Confusing Times
26 May 2020, the date that the Medical Device Regulation was originally due to apply in the EU, was a good time to take stock of where the medtech sector finds itself. Three of the most renowned and outspoken experts on the EU medical device regulatory system gave their views in this exclusive interview.